prevacid fda labelling
Aug. 21, 2008 -- The FDA is reviewing the safety of Vytorin, which combines the cholesterol-lowering drugs Zocor and Zetia, after a clinical trial linked the drug to cancer risk. In the trial, called SEAS, 4. 1% of patients taking Vytorin died of some form of cancer -- more than the 2. 5% of patients who received an inactive placebo. A recent statement issued by the study investigators noted that these differences "are small and could have occurred as a result of chance." While other clinical trial data do not indicate an increase in cancer risk, the FDA is alerting doctors and patients now while it awaits further data from the manufacturers, which they should receive in about three months. After that point, the FDA says it'll take an additional six months for a complete evaluation of the data. manufacturer prevacid prevacid maximum dosage prevacid used for prevacid babies over the counter alternative to prevacid